Druggability & Clinical Context
Druggability
Low
Score: 0.35
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
24
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Druggability Rationale: CAV1 presents low druggability (0.30 score) as a structural membrane protein lacking established drugging mechanisms and deep binding pockets suitable for small-molecule inhibition. The absence of enzymatic activity and reliance on protein-protein interactions make traditional ligand-based approaches ineffective, though indirect modulation via upregulation (e.g., Daidzein) represents an alternative therapeutic strategy.
Mechanism: No established drugging mechanism for structural membrane protein
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:Daidzein (investigational) — Natural compound, upregulates caveolin-1 expression
Structural Data:PDB (24) ✓AlphaFold ✓Cryo-EM ✓
Selectivity & Safety Considerations
CAV1 selectivity is not a primary concern given the low likelihood of small-molecule binding; however, off-target effects may arise from indirect modulation of signaling pathways dependent on caveolar function (e.g., Src kinase, nitric oxide synthase). Expression-based approaches targeting CAV1 specifically over CAV2 and CAV3 isoforms would require isoform-selective regulatory elements.